Editas Medicine (EDIT)
$9.10
0.02 (0.22%)
EDIT Stock Quote Delayed 30 Minutes
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
627.86M
PE Ratio
-2.86
EPS
-3.18
Volume (Avg. Vol.)
1.06M
Day's Range
$8.94 - $9.21
52-Week Range
$6.33 - $19.97
Dividend & Yield
N/A (N/A)
EDIT Stock Predictions, Articles, and Editas Medicine News
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip
Goldman says Editas' clinical data may underwhelm. We don't agree. So this is the time to buy the dip in EDIT stock.
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.
A Play on the Biggest Scientific Breakthrough of the Century
There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).
7 CRISPR Stocks for the Future of Medicine
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century.
Editas Medicine: 6 Things for Potential EDIT Stock Investors to Know Today
Editas Medicine (EDIT) stock is soaring higher on Monday with heavy trading despite a lack of recent news from the gene-editing company.
Gene Editing is a Major Technology to Watch
Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.
Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings
13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks
